NCT05894148View on ClinicalTrials.gov

Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Interstitial Lung Disease
Interventions
DRUG

Genakumab injection

Group 1: 120mg Q4W，group 2: 200mg Q4W

DRUG

placebo

The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.

Trial Locations (1)

Unknown

Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu

All Listed Sponsors
collaborator

Affiliated Hospital of North Sichuan Medical College

OTHER

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY